ATE265863T1 - Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung - Google Patents

Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung

Info

Publication number
ATE265863T1
ATE265863T1 AT96921486T AT96921486T ATE265863T1 AT E265863 T1 ATE265863 T1 AT E265863T1 AT 96921486 T AT96921486 T AT 96921486T AT 96921486 T AT96921486 T AT 96921486T AT E265863 T1 ATE265863 T1 AT E265863T1
Authority
AT
Austria
Prior art keywords
diagnostic
cells
therapeutic use
therapeutic
targeted agents
Prior art date
Application number
AT96921486T
Other languages
English (en)
Inventor
Evan C Unger
Dekang Shen
Guanli Wu
Original Assignee
Imarx Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27052585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE265863(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imarx Pharmaceutical Corp filed Critical Imarx Pharmaceutical Corp
Application granted granted Critical
Publication of ATE265863T1 publication Critical patent/ATE265863T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/228—Host-guest complexes, clathrates, chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
AT96921486T 1995-06-07 1996-06-06 Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung ATE265863T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49768495A 1995-06-07 1995-06-07
US64046496A 1996-05-01 1996-05-01
PCT/US1996/009938 WO1996040285A1 (en) 1995-06-07 1996-06-06 Novel targeted compositions for diagnostic and therapeutic use

Publications (1)

Publication Number Publication Date
ATE265863T1 true ATE265863T1 (de) 2004-05-15

Family

ID=27052585

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921486T ATE265863T1 (de) 1995-06-07 1996-06-06 Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung

Country Status (8)

Country Link
EP (2) EP1444991A1 (de)
JP (1) JP4215820B2 (de)
CN (2) CN1083280C (de)
AT (1) ATE265863T1 (de)
AU (1) AU709562B2 (de)
CA (1) CA2218541A1 (de)
DE (1) DE69632401T2 (de)
WO (1) WO1996040285A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5780010A (en) * 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US6548046B1 (en) 1995-06-08 2003-04-15 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6821506B2 (en) 1995-06-08 2004-11-23 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
ATE318618T1 (de) 1996-10-28 2006-03-15 Amersham Health As Verbesserungen an oder in verbindung mit diagnotischen/therapeutischen verbindungen
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6493570B1 (en) * 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
US7452551B1 (en) * 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
AU9400798A (en) * 1997-09-18 1999-04-05 University Of Pittsburgh Icam-1 selective echogenic microbubbles
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
AU750567B2 (en) † 1997-09-29 2002-07-25 Novartis Ag Stabilized preparations for use in nebulizers
EP1024837A1 (de) * 1997-10-21 2000-08-09 Nycomed Imaging As Ultraschall-abbildung mittels zielgerichten kontrastmittel und vasodilatierende wirkstoff
US20010003580A1 (en) * 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
EP1140204A2 (de) * 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronektin-rezeptor antagonist arzeimittheln
AU783647B2 (en) * 1999-04-20 2005-11-17 University Of British Columbia, The Cationic peg-lipids and methods of use
US6254852B1 (en) * 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
WO2001010450A1 (en) * 1999-08-10 2001-02-15 Imarx Therapeutics, Inc. Targeted thrombolytic agents
US7220401B2 (en) 1999-09-24 2007-05-22 Barnes-Jewish Hospital Blood clot-targeted nanoparticles
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001091805A2 (en) 2000-06-02 2001-12-06 Bracco Research Usa Compounds for targeting endothelial cells
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
AU2002214583A1 (en) * 2000-10-11 2002-04-22 Purdue Research Foundation Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US7087212B2 (en) 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
ATE508735T1 (de) 2001-12-19 2011-05-15 Novartis Ag Pulmonale verabreichung von aminoglykosiden
EP1572639A4 (de) * 2002-01-24 2006-08-09 Barnes Jewish Hospital Auf integrin zielende mittel zur bilddarstellung
EP1587944A4 (de) 2002-03-01 2007-03-21 Dyax Corp Kdr und vegf/kdr-bindende peptide und ihre diagnostische und therapeutische veranwendung bei der diagnose und therapie
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
JP2005529137A (ja) * 2002-04-29 2005-09-29 ビオテシス ゲゼルシャフト ミット ベシュレンクテル ハフツング 生体系における輸送系
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
DK2949658T3 (en) 2003-03-03 2018-10-01 Dyax Corp Peptides that specifically bind HGF receptor (cMet) and uses thereof
WO2005004781A1 (en) * 2003-06-13 2005-01-20 Imarx Therapeutics, Inc. Non-invasive intravascular thrombolyisis using modified ultrasound techniques
US7358226B2 (en) 2003-08-27 2008-04-15 The Regents Of The University Of California Ultrasonic concentration of drug delivery capsules
WO2005027808A1 (en) 2003-09-12 2005-03-31 Z-Medica Corporation Calcium zeolite hemostatic agent
CN1321697C (zh) * 2003-12-23 2007-06-20 中国人民解放军军事医学科学院毒物药物研究所 一种以磷脂类成分为成膜材料的超声造影剂组合物及其制备方法
US8012457B2 (en) * 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
CA2597940A1 (en) 2005-02-15 2006-08-24 Virginia Commonwealth University Mineral technologies (mt) for acute hemostasis and for the treatment of acute wounds and chronic ulcers
US9326995B2 (en) 2005-04-04 2016-05-03 The Regents Of The University Of California Oxides for wound healing and body repair
CN100402092C (zh) * 2005-06-07 2008-07-16 西安交通大学 血栓诊断和/或治疗用含气干粉活性剂及其制备工艺
JP2007001923A (ja) * 2005-06-23 2007-01-11 Shinshu Univ Ｎ−アセチルグルコサミン糖鎖認識タンパク質
ES2428964T3 (es) * 2005-12-09 2013-11-12 Bracco Suisse Sa Conjugados de vectores específicos de una diana-fosfolípidos
US8938898B2 (en) 2006-04-27 2015-01-27 Z-Medica, Llc Devices for the identification of medical products
US7604819B2 (en) 2006-05-26 2009-10-20 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
WO2008075192A2 (en) 2006-12-19 2008-06-26 Bracco International Bv Targeting and therapeutic compounds and gas-filled microvesicles comprising said com ounds
WO2008123478A1 (en) * 2007-03-29 2008-10-16 Canon Kabushiki Kaisha Active energy ray curable liquid composition and liquid cartridge
DE102007041832A1 (de) * 2007-09-03 2009-03-05 Siemens Ag Arzneimittel und Verfahren zur Behandlung von Prostatakrebs
SI2285350T1 (en) * 2008-06-16 2018-03-30 Pfizer Inc. Methods for the preparation of diblock copolymers functionalized with targeting agent for use in the manufacture of therapeutic nanoparticles
CN101721719B (zh) * 2008-10-28 2011-09-28 温州医学院 超声造影剂及其制备方法
CN101549161B (zh) * 2009-05-13 2010-12-01 中南大学 一种肝、脾脏特异性阳性核磁共振对比剂及其制备方法
WO2010139003A1 (en) * 2009-06-01 2010-12-09 Commonwealth Scientific And Industrial Research Organisation Chelating amphiphiles
US8858969B2 (en) 2010-09-22 2014-10-14 Z-Medica, Llc Hemostatic compositions, devices, and methods
WO2013191836A1 (en) 2012-06-22 2013-12-27 Z-Medica, Llc Hemostatic devices
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
WO2015024025A1 (en) * 2013-08-16 2015-02-19 The Regents Of The University Of California Silicone-based enteric ct contrast material
KR102031571B1 (ko) * 2014-03-07 2019-10-14 주식회사 퍼시픽시스템 약물 전달을 위해 기포를 포함하는 미셀 및 이를 제조하는 방법
US10105454B2 (en) * 2014-07-08 2018-10-23 Agency For Science, Technology And Research Ultrashort peptides as exogenous second harmonic probes for bioimaging applications
CN107205691B (zh) * 2014-10-20 2022-02-08 博迪维仁医疗有限公司 手术装置及其使用方法
CN107206111B (zh) 2014-12-31 2021-04-27 蓝瑟斯医学影像公司 脂质封装的气体微球组合物及相关方法
EP3452108A4 (de) 2016-05-04 2019-12-25 Lantheus Medical Imaging, Inc. Verfahren und vorrichtungen zur herstellung von ultraschallkontrastmitteln
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
CN110591054B (zh) * 2019-09-17 2021-05-18 江苏泰特尔新材料科技股份有限公司 一种总氯含量低、无重金属残留的环氧化物及其合成工艺
CN112266930B (zh) * 2020-10-14 2023-03-14 中国科学院苏州生物医学工程技术研究所 超声穿孔转染细胞的方法
CN113694215B (zh) * 2021-09-09 2023-12-29 南京超维景生物科技有限公司 磁性纳米滴液的组合物，磁性造影剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2060184T3 (es) * 1989-06-22 1994-11-16 Atta Moleculas anfifilicas conteniendo fluor y fosforo con propiedades tensoactivas.
US5209720A (en) * 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
IN172208B (de) * 1990-04-02 1993-05-01 Sint Sa
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
DE4232755A1 (de) * 1992-09-26 1994-03-31 Schering Ag Mikropartikelpräparationen aus biologisch abbaubaren Mischpolymeren
NZ262237A (en) * 1993-01-25 1997-06-24 Sonus Pharma Inc Ultrasound contrast agents comprising phase shift colloids having a boiling point below the body temperature of the animal it is used in
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
EP0727225A3 (de) * 1995-02-14 1997-01-15 Sonus Pharma Inc Zusammensetzungen und Verfahren zur Herstellung von gerichteter Ultraschallabbildung
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation

Also Published As

Publication number Publication date
CN1397348A (zh) 2003-02-19
CN1083280C (zh) 2002-04-24
AU709562B2 (en) 1999-09-02
CA2218541A1 (en) 1996-12-19
EP0831932A1 (de) 1998-04-01
EP0831932B1 (de) 2004-05-06
EP1444991A1 (de) 2004-08-11
JP4215820B2 (ja) 2009-01-28
DE69632401D1 (de) 2004-06-09
AU6270396A (en) 1996-12-30
DE69632401T2 (de) 2005-05-19
JPH11507638A (ja) 1999-07-06
WO1996040285A1 (en) 1996-12-19
CN1187137A (zh) 1998-07-08
EP0831932A4 (de) 2000-01-12

Similar Documents

Publication Publication Date Title
ATE265863T1 (de) Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
BR9508402A (pt) Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união
ATE317437T1 (de) Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
DE69838979D1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
CY1105212T1 (el) Αντισωματα αντι-april και κυτταρα υβριδωματος
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
WO2002036161A3 (en) Novel targeted compositions for diagnostic and therapeutic use
DE69619526T2 (de) Fgf9 als spezifischer ligand für fgfr3
ATE429450T1 (de) Chimärische dr4 antikörper und ihre verwendung
ATE348632T1 (de) Prion protein peptide und deren verwendung
BR0211614A (pt) polipeptìdeo tacis e br3 e empregos dos mesmos
ATE401348T1 (de) Immunokonjugate mit hoher bindungsaffinität
BR9609521A (pt) Fator de crescimento de tecido conectivo
DE69937294D1 (de) Von cyclophilin b abstammende tumorantigen-peptide
ATE477279T1 (de) Ganglioside-assozierte rekombinante antikörper und deren gebrauch fuer diagnose und therapien von tumoren
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
TR200003347T2 (tr) Neisseria meningitidis'denBASB029 polinükleotidleri ve polipeptidler
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
WO1999051186A3 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
GB9811221D0 (en) Bacterial-pheromones and uses therefor
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties